4.7 Review

A decade of cell death studies: Breathing new life into necroptosis

期刊

PHARMACOLOGY & THERAPEUTICS
卷 220, 期 -, 页码 -

出版社

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2020.107717

关键词

Necroptosis; Cell programmed necrosis; Cell death; RIPK1; RIPK3; MLKL; Neurodegenerative diseases; Cardiovascular disorders; Cancer

资金

  1. Michigan Ovarian Cancer Alliance (MIOCA)
  2. Marsha Rivkin Ovarian Center pilot award
  3. Elsa U. Pardee foundation
  4. Foundation for Women's Cancer
  5. Liz Tilberis early career OCRA award

向作者/读者索取更多资源

Programmed cell death (PCD) has been a major research interest in the past three decades. Initially, apoptosis was considered the only mechanistic pathway for PCD, but now other important pathways such as necroptosis have been discovered, which are crucial for understanding the cellular processes behind different pathological conditions. Additionally, research on triggering necroptosis in cancer cells to induce cell death and overcome chemoresistance is being discussed.
Programmed cell death (PCD) has been a major area of constantly growing interest over the last three decades. Originally, apoptosis was considered the only mechanistic pathway for PCD, but recently several different pathways (i.e., necroptosis, pyroptosis, ferroptosis) have emerged as important in both normal and pathological conditions. This review focuses on programmed cell necrosis (i.e., necroptosis) as a promising research direction that will help us in understanding the molecular and cellular processes behind different pathological conditions, such as chronic inflammation, neurodegeneration, and cardiovascular diseases. In addition, we discuss natural and chemical compounds and novel targeted therapies triggering necroptosis to induce cell death in cancer cells to overcome chemoresistance. (c) 2020 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据